APLMW (Apollomics) OCF Margin %: 0.00% (As of Dec. 2025)


APLMW Apollomics Inc APLMW
31 GF Score
Price $0.01
! 5 Warning Signs
View Full Analysis

What is Apollomics OCF Margin %?

Apollomics APLMW -7.91% 31 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates APLMW with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 959 Biotechnology companies, Apollomics ranks worse than 56.73% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Apollomics's Cash Flow from Operations for the six months ended in Dec. 2025 was $-2.75 Mil. Apollomics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Apollomics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Apollomics's current OCF Yield % is 0.00%.

The historical rank and industry rank for Apollomics's OCF Margin % or its related term are showing as below:


During the past 6 years, the highest OCF Margin % of Apollomics was -121.99%. The lowest was -121.99%. And the median was -121.99%.

APLMW's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Apollomics OCF Margin % Related Terms

Apollomics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Apollomics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics OCF Margin % Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -121.99

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -89.69 0.00
APLMW
31GF Score
Apollomics Inc APLMW
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Apollomics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-10.369/8.5
=-121.99 %

Apollomics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.745/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Apollomics (APLMW) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Apollomics and its competitors. According to the industry distribution chart, Apollomics ranks #544 out of 959 companies in the Biotechnology industry, placing it in the top 56.7%.
Is Apollomics' OCF Margin % too high?
Apollomics' current OCF Margin % is 0.00%. Based on the distribution chart, Apollomics ranks #544 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' OCF Margin % compare to TVRD and PLRZ?
According to the Biotechnology industry distribution chart, Apollomics ranks #544 out of 959 companies for OCF Margin %. This places Apollomics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Apollomics and its competitors. Apollomics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Apollomics' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Apollomics (APLMW), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score

Get the complete analysis for APLMW

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price